DK1947093T3 - Substituerede morpholin og thiomorpholin derivater - Google Patents

Substituerede morpholin og thiomorpholin derivater

Info

Publication number
DK1947093T3
DK1947093T3 DK08007169.9T DK08007169T DK1947093T3 DK 1947093 T3 DK1947093 T3 DK 1947093T3 DK 08007169 T DK08007169 T DK 08007169T DK 1947093 T3 DK1947093 T3 DK 1947093T3
Authority
DK
Denmark
Prior art keywords
substituted morpholine
thiomorpholine derivatives
thiomorpholine
derivatives
morpholine
Prior art date
Application number
DK08007169.9T
Other languages
Danish (da)
English (en)
Inventor
Mario Rottlaender
Nikolay Khanzhin
Andreas Ritzen
William Patrick Watson
Thornoee Christian Wenzel
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37730781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1947093(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK1947093T3 publication Critical patent/DK1947093T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK08007169.9T 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater DK1947093T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55257404P 2004-03-12 2004-03-12
DKPA200400412 2004-03-12
EP05706819A EP1727809B8 (en) 2004-03-12 2005-03-09 Substituted morpholine and thiomorpholine derivatives

Publications (1)

Publication Number Publication Date
DK1947093T3 true DK1947093T3 (da) 2010-02-01

Family

ID=37730781

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05706819T DK1727809T3 (da) 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater
DK08007169.9T DK1947093T3 (da) 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05706819T DK1727809T3 (da) 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater

Country Status (32)

Country Link
US (6) US7501414B2 (US08012962-20110906-C00001.png)
EP (3) EP2138487A1 (US08012962-20110906-C00001.png)
JP (1) JP5006184B2 (US08012962-20110906-C00001.png)
KR (2) KR101411204B1 (US08012962-20110906-C00001.png)
CN (2) CN102516204B (US08012962-20110906-C00001.png)
AR (1) AR049784A1 (US08012962-20110906-C00001.png)
AT (2) ATE398112T1 (US08012962-20110906-C00001.png)
AU (1) AU2005221762B2 (US08012962-20110906-C00001.png)
BR (1) BRPI0508570B8 (US08012962-20110906-C00001.png)
CA (1) CA2559397C (US08012962-20110906-C00001.png)
CO (1) CO5721001A2 (US08012962-20110906-C00001.png)
CY (2) CY1110392T1 (US08012962-20110906-C00001.png)
DE (2) DE602005007474D1 (US08012962-20110906-C00001.png)
DK (2) DK1727809T3 (US08012962-20110906-C00001.png)
EA (1) EA015120B1 (US08012962-20110906-C00001.png)
EG (1) EG25344A (US08012962-20110906-C00001.png)
ES (2) ES2334076T3 (US08012962-20110906-C00001.png)
HK (1) HK1172618A1 (US08012962-20110906-C00001.png)
HR (1) HRP20090685T1 (US08012962-20110906-C00001.png)
IL (1) IL177859A (US08012962-20110906-C00001.png)
MY (2) MY147786A (US08012962-20110906-C00001.png)
NO (1) NO337161B1 (US08012962-20110906-C00001.png)
NZ (1) NZ549133A (US08012962-20110906-C00001.png)
PL (2) PL1947093T3 (US08012962-20110906-C00001.png)
PT (2) PT1727809E (US08012962-20110906-C00001.png)
RS (2) RS51066B (US08012962-20110906-C00001.png)
SG (1) SG151254A1 (US08012962-20110906-C00001.png)
SI (2) SI1947093T1 (US08012962-20110906-C00001.png)
TW (2) TWI349666B (US08012962-20110906-C00001.png)
UA (2) UA102517C2 (US08012962-20110906-C00001.png)
WO (1) WO2005087754A1 (US08012962-20110906-C00001.png)
ZA (2) ZA200607286B (US08012962-20110906-C00001.png)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
MX2007010547A (es) * 2005-03-03 2007-10-03 Lundbeck & Co As H Derivados de piridina sustituidos.
UA92340C2 (en) * 2005-03-03 2010-10-25 Х. Луннбек А/С Substituted pyridine derivatives
KR20080096659A (ko) 2006-02-07 2008-10-31 하. 룬트벡 아크티에 셀스카브 정신분열증 증상의 치료 또는 감소를 위한 ｋｃｎｑ개방제의 용도
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
KR20090079191A (ko) 2006-08-23 2009-07-21 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서 ４-(ｎ-아자사이클로알킬) 아닐리드의 유도체
CN101578259A (zh) 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
MX2010001171A (es) * 2007-08-01 2010-03-01 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico.
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US20100286138A1 (en) * 2009-05-11 2010-11-11 H. Lundbeck A/S Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
WO2011026891A1 (en) * 2009-09-07 2011-03-10 Neurosearch A/S Substituted pyridine derivatives and their medical use
AU2011275393B2 (en) 2010-07-08 2014-04-10 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
EP2844247A4 (en) * 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
CN103044431A (zh) * 2012-10-22 2013-04-17 中国药科大学 制备五氟磺草胺的新方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA2969756A1 (en) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
EP3917907A1 (en) 2019-01-29 2021-12-08 Universitá Degli Studi Di Salerno Modulators of potassium ion channels and uses thereof
IL282188A (en) * 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03175086A (ja) * 1989-09-14 1991-07-30 Fuji Photo Film Co Ltd ジアゾ感熱記録材料
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
AU6645998A (en) 1996-12-23 1998-07-17 Du Pont Pharmaceuticals Company Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
CN1246847A (zh) * 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
WO1999032454A1 (en) 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
WO1999050255A2 (en) 1998-03-27 1999-10-07 Du Pont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
WO2001010381A2 (en) * 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
IL152202A0 (en) 2000-05-26 2003-05-29 Bristol Myers Squibb Co Human kcnq5 polypeptide and pharmaceutical compositions containing the same
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
MXPA03006268A (es) * 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos terapeuticos de cromano.
CA2434015A1 (en) * 2001-01-16 2002-07-18 Astrazeneca Ab Therapeutic chroman compounds
CN1250519C (zh) * 2001-01-19 2006-04-12 中国人民解放军军事医学科学院毒物药物研究所 具有调节钾通道功能的胺衍生物及其制备方法和应用
PL372944A1 (en) * 2001-02-20 2005-08-08 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives

Also Published As

Publication number Publication date
PT1947093E (pt) 2009-12-22
KR20120136422A (ko) 2012-12-18
EP1947093B1 (en) 2009-09-23
US7632835B2 (en) 2009-12-15
NO337161B1 (no) 2016-02-01
CN102516204B (zh) 2016-01-20
NO20064599L (no) 2006-12-08
EA200601686A1 (ru) 2007-02-27
SI1947093T1 (sl) 2010-01-29
UA102517C2 (ru) 2013-07-25
PL1727809T3 (pl) 2008-11-28
EP1947093B9 (en) 2010-03-03
TWI357901B (en) 2012-02-11
US20110294787A1 (en) 2011-12-01
ZA200709718B (en) 2008-09-25
HK1172618A1 (zh) 2013-04-26
TW200811121A (en) 2008-03-01
US20100063036A1 (en) 2010-03-11
ATE398112T1 (de) 2008-07-15
EP1727809B1 (en) 2008-06-11
KR101411204B1 (ko) 2014-06-23
US20090143369A1 (en) 2009-06-04
IL177859A (en) 2013-02-28
CY1110392T1 (el) 2015-04-29
US7812023B2 (en) 2010-10-12
US20090137571A1 (en) 2009-05-28
JP2007528880A (ja) 2007-10-18
ES2334076T3 (es) 2010-03-04
US8299075B2 (en) 2012-10-30
EP2138487A1 (en) 2009-12-30
DE602005007474D1 (en) 2008-07-24
SI1727809T1 (sl) 2008-10-31
EP1727809A1 (en) 2006-12-06
BRPI0508570A (pt) 2007-08-14
RS51066B (sr) 2010-10-31
CN1930138A (zh) 2007-03-14
CA2559397A1 (en) 2005-09-22
PT1727809E (pt) 2008-08-13
MY147786A (en) 2013-01-31
EP1727809B8 (en) 2008-10-29
US20060167248A1 (en) 2006-07-27
AU2005221762B2 (en) 2011-06-09
ES2306087T3 (es) 2008-11-01
WO2005087754A1 (en) 2005-09-22
US20100063033A1 (en) 2010-03-11
EG25344A (en) 2011-12-14
US7501414B2 (en) 2009-03-10
TW200533359A (en) 2005-10-16
RS50606B (sr) 2010-05-07
US8012962B2 (en) 2011-09-06
MY143698A (en) 2011-06-30
ATE443702T1 (de) 2009-10-15
ZA200607286B (en) 2008-04-30
EP1947093A1 (en) 2008-07-23
CA2559397C (en) 2010-08-10
DE602005016849D1 (de) 2009-11-05
NZ549133A (en) 2010-09-30
IL177859A0 (en) 2006-12-31
CN102516204A (zh) 2012-06-27
DK1727809T3 (da) 2008-09-29
AR049784A1 (es) 2006-09-06
CO5721001A2 (es) 2007-01-31
TWI349666B (en) 2011-10-01
UA90670C2 (en) 2010-05-25
JP5006184B2 (ja) 2012-08-22
KR20060128004A (ko) 2006-12-13
HRP20090685T1 (hr) 2010-02-28
CY1109656T1 (el) 2014-08-13
BRPI0508570B8 (pt) 2021-05-25
PL1947093T3 (pl) 2010-02-26
EA015120B1 (ru) 2011-06-30
BRPI0508570B1 (pt) 2018-11-21
SG151254A1 (en) 2009-04-30
AU2005221762A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
DK1727809T3 (da) Substituerede morpholin og thiomorpholin derivater
CY2015036I1 (el) Νεα παραγωγα οξαζολιδινονης
NO20054224D0 (no) Nye 2-pyridinkarboksamidderivater
IS8180A (is) Nýjar besímídasólafleiður
DK1771421T3 (da) N-hydroxyamidderivater og anvendelse deraf
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
DK1709018T3 (da) Acylaminothiazolderivater og anvendelse deraf som beta-amyloid-hæmmere
DK1902050T3 (da) Oxazolidinonderivater og anvendelse deraf som antibiotika
IS7980A (is) Díarýlmetýlídenpíperidínafleiður, framleiðsla þeirra og notkun
DE602004013236D1 (de) Messgerät
DE60323851D1 (de) TAP Multiplexer
DK1658592T3 (da) Skriver og en skrivers funktion
DE502005001764D1 (de) Erweiterbares Steuergerät
DE602004000384D1 (de) Numerische Steuereung
DE602004008130D1 (de) Messuhr
DK1631229T3 (da) Oppustelig pude
DE10349030B4 (de) Axialverstellvorrichtung
FI20031829A (fi) Mittalaitteen tiiviste
ATE497743T1 (de) Expandierbares bandscheibenimplantat
ATA17922003A (de) Portioniervorrichtung
DE50307008D1 (de) Rollenschneideinrichtung
ES1055831Y (es) Sabana bajera ajustable.
AT6960U3 (de) Spülkasten
DK1951687T3 (da) N-hydroxyamid-derivater og deres anvendelse
SE0302779D0 (sv) Ställbar säng